Kuklenski v. Medtronic USA, Inc.

CourtDistrict Court, D. Minnesota
DecidedOctober 12, 2022
Docket0:22-cv-00438
StatusUnknown

This text of Kuklenski v. Medtronic USA, Inc. (Kuklenski v. Medtronic USA, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Minnesota primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Kuklenski v. Medtronic USA, Inc., (mnd 2022).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF MINNESOTA

Jan Kuklenski, File No. 22-cv-438 (ECT/JFD)

Plaintiff,

v. OPINION AND ORDER

Medtronic USA, Inc.,

Defendant.

Pamela M. Spera and Clayton D. Halunen, Halunen Law, Minneapolis, MN, for Plaintiff Jan Kuklenski.

Marko J. Mrkonich, Claire B. Deason, and Daniel Bihrle, Littler Mendelson, PC, Minneapolis, MN, for Defendant Medtronic USA, Inc.

Plaintiff Jan Kuklenski is a Michigan citizen who worked for Minnesota-based Medtronic USA, Inc. In this suit, Kuklenski alleges that Medtronic unlawfully terminated her employment after she took medical leave. She asserts statutory claims under the Minnesota Human Rights Act, the federal Family and Medical Leave Act, and the Minnesota Whistleblower Act, and a promissory estoppel claim under unspecified state common law.1

1 At least as filed, there is federal-question and diversity-of-citizenship subject-matter jurisdiction over Kuklenski’s Complaint. Kuklenski’s claim under the Family and Medical Leave Act obviously raises a federal question. 28 U.S.C. § 1331. As for diversity jurisdiction, Kuklenski alleges facts plausibly showing that the matter in controversy exceeds the sum of $75,000. Compl. [ECF No. 1] ¶¶ 42, 47, 56, 64, 72. And there is complete diversity of citizenship. Kuklenski is a Michigan citizen, and Medtronic is a Minnesota citizen. Compl. ¶¶ 2, 3, 6; see Off. Minn. Sec’y State, Business Record Details: Medtronic USA, Inc., Medtronic seeks dismissal of the case under Federal Rules of Civil Procedure 12(b)(1) and 12(b)(6). Medtronic’s motion will be granted in part under Rule 12(b)(6). Difficult legal and factual questions remain regarding whether Kuklenski has statutory

standing to assert a claim under the Minnesota Human Rights Act; the better answer at this early stage is to allow those claims to proceed. The motion also will be denied with respect to Kuklenski’s claim under the Minnesota Whistleblower Act because Kuklenski alleges facts plausibly showing that she engaged in protected activity, the only element Medtronic challenges. The motion will be granted as to Kuklenski’s claims under the Family Medical

Leave Act and her promissory estoppel claim. Kuklenski has failed to allege facts plausibly showing essential elements of these two claims. I2

Kuklenski is a long-time Medtronic employee. Kuklenski began her Medtronic employment in 1999 as a Cardiovascular Account Manager. Compl. [ECF No. 1] ¶ 9.3 She would go on to hold other positions at Medtronic. Of particular relevance here, in

https://mblsportal.sos.state.mn.us/Business/SearchDetails?filingGuid=dee866a5-b1d4- e011-a886-001ec94ffe7f (last visited Oct. 10, 2022).

2 In accordance with the standards governing a Rule 12(b)(6) motion, the facts are drawn entirely from Kuklenski’s Complaint. Hartman v. Bowles, 39 F.4th 544, 545 (8th Cir. 2022).

3 Medtronic says that “at the time her employment ended,” Kuklenski was employed by “Medtronic Integrated Health Solutions LLC, a wholly owned subsidiary of Medtronic USA.” Def.’s Mem. in Supp. [ECF No. 7] at 1 n.1; see Harris Decl. [ECF No. 7-1] ¶ 4. If correct, and assuming this means Medtronic USA, Inc. is the LLC’s sole member, then substituting the LLC as the named Defendant would not affect the presence of diversity jurisdiction. See E3 Biofuels, LLC v. Biothane, LLC, 781 F.3d 972, 975 (8th Cir. 2015) (recognizing that an LLC’s citizenship is that of its member or members). December 2018, Kuklenski became “Senior Director, Value Based Healthcare (“VBHC”) Partnership Lead, Americas.” Id. ¶ 10. Though the precise duties of Kuklenski’s position are not clear from the Complaint,

she worked frequently in Minnesota and had frequent contacts with Minnesota-based supervisors and personnel. Though a Michigan citizen, Kuklenski “routinely visited Minnesota for work over the course of her career with [Medtronic]; in her 22 years of employment, [she] was physically present in Minnesota for work approximately 20% of the time.” Id. ¶ 7. As part of her employment, Kuklenski also had regular remote contact

with Minnesota-based Medtronic personnel. She describes these contacts in a single paragraph of her Complaint. There, she alleges to have “regularly reported to four different Minneapolis-based supervisors[,]” had “numerous” contacts with other Minnesota-based Medtronic personnel, participated in many “zoom calls and phone calls[,]” and observed live broadcasts of periodic meetings. Id. ¶ 8.

Kuklenski was asked—and agreed—to remain at Medtronic through a reorganization and take on additional responsibilities. In January 2021, during “an asserted Medtronic reorganization,” Medtronic Vice President Linda Engels asked Kuklenski to remain at Medtronic “to assist … with pressing transition issues and to manage all four VBHC partnerships.” Id. ¶ 13. To that point, Kuklenski had managed just

two of those partnerships. Id. Kuklenski agreed “on the explicit condition that her compensation, compensation structure, and title would remain the same.” Id. ¶ 14. On January 26, Engels agreed to those conditions. Id. ¶ 15. By staying with Medtronic through the reorganization, Kuklenski missed out on fifty-two weeks’ worth of severance pay she would have received had her employment terminated as part of the reorganization. Id. ¶ 14. Medtronic altered Kuklenski’s compensation structure a few months later. On May

27, 2021, Medtronic changed Kuklenski’s compensation from the “Medtronic Incentive Plan for non-commercial sales (“MIP”) to a Sales Incentive Plan (“SIP”), a commission structured plan.” Id. ¶ 16. The inference is that Kuklenski’s compensation shifted from one that provided more guaranteed compensation to one that provided more commission- based compensation.

Kuklenski objected to the change. On June 1, Kuklenski asked to return to the MIP structure so that she and Medtronic would be “viewed as a trusted partner” in the VBHC relationships. Id. ¶ 17. Kuklenski explained that the MIP structure had “differentiated [them] from the many strategic suppliers attempting to emulate Medtronic.” Id. ¶ 18. Kuklenski also wrote to her “direct boss,” Joe Hensley, about the change. Id. ¶ 19. She

“detailed, in writing, how the SIP compensation plan failed to adhere to Medtronic’s” agreements with the four partnerships she managed (“VBHP Agreements”). Id.. Kuklenski wrote that the change violated a “clear and mutual understanding” that she would “represent Medtronic as a VBHC leader, unencumbered by a SIP, a sale, or a product” and “that the commercial and VBHC work must remain separate.” Id. ¶¶ 20–21.

Soon after objecting to her changed compensation structure, Kuklenski took FMLA leave. The leave began on June 7. Id. ¶ 22. Kuklenski suffered from “an inner ear disease” that caused her “serious health problems,” and her leave was for “required surgery and time off to heal.” Id. The surgery was “more extensive and invasive than her surgeon had anticipated,” so Kuklenski “requested an extension of her leave until December 7, 2021, when she was prepared to return to work with no restrictions.” Id. ¶ 23. On September 15, after receiving the extension request, Senior Employee Relations Manager Rochelle Harris

informed Kuklenski: “In order to meet our ongoing business needs, we are posting your position for sourcing and recruitment purposes. If your position is still available when you are released to return to work full time, you may report back to that same position.” Id. ¶ 24. Medtronic filled Kuklenski’s position. On October 6, Harris emailed Kuklenski that

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Gwendolyn Donald v. Sybra, Incorporated
667 F.3d 757 (Sixth Circuit, 2012)
Mary Sisk v. Picture People, Inc.
669 F.3d 896 (Eighth Circuit, 2012)
Ben J. Friedman v. Brw, Inc. Craig A. Amundsen
40 F.3d 293 (Eighth Circuit, 1994)
Judy L. Fox v. T-H Continental Limited Partnership
78 F.3d 409 (Eighth Circuit, 1996)
Paul J. Kiel v. Select Artificials, Inc.
169 F.3d 1131 (Eighth Circuit, 1999)
Porous Media Corporation v. Pall Corporation
186 F.3d 1077 (Eighth Circuit, 1999)
Smith v. Allen Health Systems
302 F.3d 827 (Eighth Circuit, 2002)
Laura Kincaid v. City of Omaha
378 F.3d 799 (Eighth Circuit, 2004)
Kathleen Marez v. Saint-Gobain Containers, Inc.
688 F.3d 958 (Eighth Circuit, 2012)
Miller v. Redwood Toxicology Laboratory, Inc.
688 F.3d 928 (Eighth Circuit, 2012)
Pulczinski v. Trinity Structural Towers, Inc.
691 F.3d 996 (Eighth Circuit, 2012)
Tanya Bosley v. Cargill Meat Solutions Corp.
705 F.3d 777 (Eighth Circuit, 2013)
June Brown v. City of Jacksonville
711 F.3d 883 (Eighth Circuit, 2013)
David Longaker v. Boston Scientific Corporation
715 F.3d 658 (Eighth Circuit, 2013)
Dumas v. Kessler & Maguire Funeral Home, Inc.
380 N.W.2d 544 (Court of Appeals of Minnesota, 1986)

Cite This Page — Counsel Stack

Bluebook (online)
Kuklenski v. Medtronic USA, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/kuklenski-v-medtronic-usa-inc-mnd-2022.